Journal Menu
► ▼ Journal Menu-
- Current Oncology Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Volumes not published by MDPI
Need Help?
Announcements
6 November 2025
MDPI Launches the Michele Parrinello Award for Pioneering Contributions in Computational Physical Science
MDPI is delighted to announce the establishment of the Michele Parrinello Award. Named in honor of Professor Michele Parrinello, the award celebrates his exceptional contributions and his profound impact on the field of computational physical science research.
The award will be presented biennially to distinguished scientists who have made outstanding achievements and contributions in the field of computational physical science—spanning physics, chemistry, and materials science.
About Professor Michele Parrinello
"Do not be afraid of new things. I see it many times when we discuss a new thing that young people are scared to go against the mainstream a little bit, thinking what is going to happen to me and so on. Be confident that what you do is meaningful, and do not be afraid, do not listen too much to what other people have to say.”
——Professor Michele Parrinello
![]() |
Born in Messina in 1945, he received his degree from the University of Bologna and is currently affiliated with the Italian Institute of Technology. Professor Parrinello is known for his many technical innovations in the field of atomistic simulations and for a wealth of interdisciplinary applications ranging from materials science to chemistry and biology. Together with Roberto Car, he introduced ab initio molecular dynamics, also known as the Car–Parrinello method, marking the beginning of a new era both in the area of electronic structure calculations and in molecular dynamics simulations. He is also known for the Parrinello–Rahman method, which allows crystalline phase transitions to be studied by molecular dynamics. More recently, he has introduced metadynamics for the study of rare events and the calculation of free energies. |
For his work, he has been awarded many prizes and honorary degrees. He is a member of numerous academies and learned societies, including the German Berlin-Brandenburgische Akademie der Wissenschaften, the British Royal Society, and the Italian Accademia Nazionale dei Lincei, which is the major academy in his home country of Italy.
Award Committee
![]() |
The award committee will be chaired by Professor Xin-Gao Gong, a computational condensed matter physicist, academician of the Chinese Academy of Sciences, and professor at the Department of Physics, Fudan University. Professor Xin-Gao Gong will lead a panel of several senior experts in the field to oversee the evaluation and selection process. The Institute for Computational Physical Sciences at Fudan University (Shanghai, China), led by Professor Xin-Gao Gong, will serve as the supporting institute for the award. |
"We hope the Michele Parrinello Award will recognize scientists who have made significant contributions to the field of computational condensed matter physics and at the same time set a benchmark for the younger generation, providing clear direction for their pursuit—this is precisely the original intention behind establishing the award."
——Professor Xin-Gao Gong
The first edition of the award was officially launched on 1 November 2025. Nominations will be accepted before the end of March 2026. For further details, please visit mparrinelloaward.org.
About the MDPI Sustainability Foundation and MDPI Awards 
The Michele Parrinello Award is part of the MDPI Sustainability Foundation, which is dedicated to advancing sustainable development through scientific progress and global collaboration. The foundation also oversees the World Sustainability Award, the Emerging Sustainability Leader Award, and the Tu Youyou Award. The establishment of the Michele Parrinello Award will further enrich the existing award portfolio, providing continued and diversified financial support to outstanding professionals across various fields.
In addition to these foundation-level awards, MDPI journals also recognize outstanding contributions through a range of honors, including Best Paper Awards, Outstanding Reviewer Awards, Young Investigator Awards, Travel Awards, Best PhD Thesis Awards, Editor of Distinction Awards, and others. These initiatives aim to recognize excellence across disciplines and career stages, contributing to the long-term vitality and sustainability of scientific research.
Find more information on awards here.
3 February 2026
World Cancer Day—“United by Unique”, 4 February 2026
World Cancer Day draws global attention to the ongoing fight against cancer—one of the leading causes of morbidity and mortality worldwide. Observed annually on 4 February, World Cancer Day unites individuals, communities, researchers, clinicians, and policymakers in a shared commitment to reduce the global cancer burden and improve outcomes for patients everywhere.
Aligned with this year’s theme and the United Nations Sustainable Development Goal 3 (Good Health and Well-Being), the initiative calls for greater awareness, early detection, equitable access to care, and sustained investment in cancer research and innovation. From prevention and diagnosis to treatment and survivorship, addressing cancer requires coordinated, multidisciplinary efforts across healthcare systems and scientific communities worldwide.
In support of World Cancer Day, selected MDPI journals highlight cutting-edge research across the cancer continuum, including advances in oncology, diagnostics, therapeutics, public health, and patient-centred care. Through curated articles, Special Issues, and expert-led webinars, these journals aim to foster knowledge exchange and collaboration to accelerate progress toward a future where cancer prevention and treatment are accessible, effective, and equitable for all.

![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |

In 2026, MDPI is honored to support World Cancer Day through a monthly awareness ries beginning in February. Each session will focus on a key cancer awareness theme, showcasing cutting-edge research and expert insights through specially curated landing pages and a dedicated webinar series. Through this special activity, we aim to sustain engagement and cross-disciplinary collaboration throughout the year. Below is the list of events. You may click on the respective links (updated throughout the year, closer to each event month) to access the individual event pages.
| Month | Relevant Cancer Awareness Month |
| January | Cervical Cancer Awareness Month |
| February | National Cancer Prevention Month |
| March | Colorectal Cancer Awareness Month |
| April | Esophageal Cancer Awareness Month |
| May | Bladder Cancer Awareness Month |
| June | Cancer Survivorship Awareness Month |
| July | Sarcoma and Bone Cancer Awareness Month |
| August | Brain Cancer Awareness Month |
| September | Childhood Cancer Awareness Month |
| October | Breast Cancer Awareness Month |
| November | Lung Cancer Awareness Month |
| December | Skin Cancer Awareness Month |

|
|
|||
![]() |
![]() |
![]() |
![]() |
|
Dr. Xiang Xue, |
Dr. Federico Pio Fabrizio, |
Dr. Anis Ahmad, |
Dr. Hiroaki Kiyokawa, |
Register for this webinar for free here!

“Molecular Insight and Antioxidative Therapeutic Potentials of Plant-Derived Compounds in Breast Cancer Treatment”
by Sandhya Shukla, Arvind Kumar Shukla, Adarsha Mahendra Upadhyay, Navin Ray, Fowzul Islam Fahad, Arulkumar Nagappan, Sayan Deb Dutta and Raj Kumar Mongre
Onco 2025, 5(2), 27; https://doi.org/10.3390/onco5020027
“Comprehensive Analysis of Advancement in Optical Biosensing Techniques for Early Detection of Cancerous Cells”
by Ayushman Ramola, Amit Kumar Shakya and Arik Bergman
Biosensors 2025, 15(5), 292; https://doi.org/10.3390/bios15050292
“Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies”
by Valencia Mc Neil and Seung Won Lee
Cancers 2025, 17(9), 1408; https://doi.org/10.3390/cancers17091408
“Prunin: An Emerging Anticancer Flavonoid”
by Juie Nahushkumar Rana and Sohail Mumtaz
Int. J. Mol. Sci. 2025, 26(6), 2678; https://doi.org/10.3390/ijms26062678
“Advancing Cancer Therapy with Quantum Dots and Other Nanostructures: A Review of Drug Delivery Innovations, Applications, and Challenges”
by Ashutosh Pareek, Deepanjali Kumar, Aaushi Pareek and Madan Mohan Gupta
Cancers 2025, 17(5), 878; https://doi.org/10.3390/cancers17050878
“From Bench to Bedside: Transforming Cancer Therapy with Protease Inhibitors”
by Alireza Shoari
Targets 2025, 3(1), 8; https://doi.org/10.3390/targets3010008
“Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells”
by Tânia Moura, Paula Laranjeira, Olga Caramelo, Ana M. Gil and Artur Paiva
Curr. Oncol. 2025, 32(3), 143; https://doi.org/10.3390/curroncol32030143
“Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer”
by Jennifer Haynes and Prasath Manogaran
Int. J. Mol. Sci. 2025, 26(5), 1988; https://doi.org/10.3390/ijms26051988
“Polyphenol-Based Prevention and Treatment of Cancer Through Epigenetic and Combinatorial Mechanisms”
by Neha Singaravelan and Trygve O. Tollefsbol
Nutrients 2025, 17(4), 616; https://doi.org/10.3390/nu17040616
“Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment”
by Fatih Ciftci, Ali Can Özarslan, İmran Cagri Kantarci, Aslihan Yelkenci, Ozlem Tavukcuoglu and Mansour Ghorbanpour
Pharmaceutics 2025, 17(1), 121; https://doi.org/10.3390/pharmaceutics17010121

|
“Genetic and Epigenetic Analyses in Cancer” |
“Improving the Quality of Life in Patients with Gynecological Cancer” |
![]() |
![]() |
|
“Antibody-Mediated Therapy and Other Emerging Therapies in Cancer Treatment” |
“Advances in Implementation Science and Knowledge Mobilization for Cancer Control” |
![]() |
![]() |

![]() |
![]() |
![]() |
2 February 2026
MDPI INSIGHTS: The CEO's Letter #31 - MDPI 30 Years, 500 Journals, UK Summit, Z-Forum Conference, APE
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts

MDPI at 30: Three Decades of Open Science, Built Together
As we begin 2026, we approach a meaningful milestone in MDPI’s history: 30 years of advancing Open Science.
What began in 1996 as a small, researcher-driven initiative has grown into a global open-access publisher, supporting hundreds of journals, millions of researchers, and a shared belief that scientific knowledge should be openly available to all. Over these three decades, Open Access has moved from the margins to the mainstream, and MDPI has been proud to help shape that transformation.
To mark this anniversary year, we are pleased to share our MDPI 30th Anniversary logo.
The Anniversary logo is intentionally simple, confident, and enduring, designed to work across cultures, disciplines, and digital environments. It reflects both continuity and progress, honouring MDPI’s established identity while representing the company we are today. The green accent symbolizes our connection to the research communities we serve and the collaborative nature of Open Science itself.
Alongside the visual identity, we are also introducing our 30th Anniversary tagline:
30 Years of Open Science, Built Together.

This phrase captures what has always defined MDPI. Open Science is not the work of a single organization: it is a collective effort shaped by researchers, editors, reviewers, institutions, and the many teams who support the publishing process every day. MDPI’s role has been to provide the infrastructure and commitment that allow this collaboration to thrive.
Throughout 2026, we will mark this anniversary through regional events, global conversations, and editorial initiatives that reflect on MDPI’s evolution, its impact across disciplines, and the communities that make this work possible.
“Open Science is a collective effort”
Whether you have been part of MDPI’s journey for decades or are engaging with us for the first time this year, this milestone belongs to all of us. The past 30 years have shown what is possible when openness, trust, and collaboration are placed at the centre of scholarly communication.
As we look ahead, our focus remains clear: continuing to strengthen quality, integrity, and partnership – so that Open Science can keep moving forward, together.
Impactful Research

A Shared Milestone: MDPI’s Journal Portfolio Reaches 500 Titles
MDPI has reached an important milestone: our journal portfolio grew to more than 500 academic journals last year, spanning the fields of chemistry, engineering, biology, medicine, environmental sciences, the social sciences, and beyond.
The number itself is significant, but what matters more is what supports it: hundreds of scholarly communities that have chosen to collaborate, grow, and publish with MDPI.
From our beginnings nearly 30 years ago with a single Open Access journal (Molecules), MDPI has been guided by a simple aim: advancing Open Science. Reaching 500 journals is not an endpoint. It reflects the diversity of disciplines, ideas, and research cultures that now form part of our shared ecosystem.
Growth with Purpose
Every journal exists because a specific community believes there is a need for focus, visibility, and dialogue in a particular field. As our portfolio has expanded, so has our responsibility to ensure that scale is matched with strong editorial standards, robust research integrity practices, and meaningful academic leadership.
This milestone comes as we enter MDPI’s 30th anniversary year, a fitting moment to reflect on what scale in scholarly publishing truly requires: not only reach, but also dedicated long-term stewardship.
New Journals, New Communities
In December 2025 alone, MDPI welcomed eight newly launched journals and three journal transfers (details below), all of which published their inaugural issues by year-end.

Each of these journals is shaped by its Editors-in-Chief, Associate Editors, and Editorial Board Members, who define its scope, standards, and direction. We are grateful for the time, expertise, and commitment they bring to building these new communities.
Welcoming Transferred and Acquired Journals
We were pleased to publish the first MDPI issues of three recently transferred or acquired journals:
- Cardiovascular Medicine – advancing research on the prevention, diagnosis, and treatment of cardiovascular disease
- Germs – addressing infectious diseases through clinical, public health, and translational perspectives
- Romanian Journal of Preventive Medicine (RJPM) – supporting population health, early detection, and preventive care in collaboration with the Romanian Society of Preventive Medicine
Each of these journals brings an established identity and legacy. Our role is to support their continued development with the same editorial rigor, transparency, and Open Access principles that guide our broader portfolio.
A Collective Achievement
Reaching more than 500 journals is not the achievement of any single team or individual. It is the result of collaboration across the entire scholarly ecosystem. As such, I would like to thank our authors, reviewers, academic editors, and Editorial Board Members, as well as our colleagues across MDPI, who support these communities every day.
As we look ahead, we will continue to expand the breadth and depth of our publishing activities while remaining attentive to the evolving expectations of Open Science, research integrity, and responsible growth.
This milestone is a reminder that Open Access publishing is not only about making research available. It is about building platforms where knowledge can be shared, challenged, improved, and trusted, at scale, and with care.
Inside Research

MDPI UK Summit 2026 in Manchester (21–22 January)
On 21–22 January, we had the pleasure of hosting the MDPI UK Summit 2026 in Manchester. Over two days, we welcomed more than 20 Editors-in-Chief (EiC), Section Editors-in-Chief (SEiC), and Associate Editors for an open, in-depth conversations about how MDPI supports Open Science, editorial independence, and research standards across our journals.
What stood out most was not just the quality of the discussions, but the openness, curiosity, and mutual respect that shaped every session.
|
|
|
|
|
|
|
|
What We Covered
The programme was designed to give insight into how MDPI works behind the scenes and how different teams collaborate to support our journals and editors. Topics included:
- MDPI overview and the evolving Open Access market
- MDPI–UK collaboration and local engagement
- Editorial and peer-review processes
- Research integrity and publication ethics
- Institutional partnerships
- Indexing, journal development, and academic community engagement
Sessions were led by MDPI colleagues across editorial, research integrity, indexing, partnerships, and UK operations, showing how cross-functional our work truly is.
What We Heard
The feedback from editors was both encouraging and grounding:
- 92% rated the Summit Excellent (8% Good)
- 100% said their understanding of MDPI’s values, editorial processes, and local collaborations had significantly improved
- 69% attended primarily to stay informed about academic publishing and research integrity
- 85% felt fully heard and engaged
A few comments that stayed with me:
- “Today’s event truly gave me the opportunity to see the heart of MDPI UK.”
- “The summit was very informative – I really enjoyed seeing the behind-the-scenes operations.”
- “Keep being open to discussions and making editors feel part of the MDPI family.”
These reflections remind us that transparency, listening, and dialogue are not nice-to-haves: they are foundational to trust.
|
|
|
|
Looking Ahead
The UK Summit is one of more than 10 MDPI Summits we are organizing this year across North America, Europe, and APAC. Each one is an investment in relationships, shared understanding, and improvement.
Thank you to the MDPI UK team and supporting colleagues across departments who made this event possible. This was a positive step in strengthening our editorial engagement and kicking off a year of MDPI Summits.
Coming Together for Science

Recapping the Z-Forum 2026 Conference on Sustainability and Innovation (15–16 January 2026)
In January, MDPI supported and participated in the Z-Forum on Sustainability and Innovation, held across Zurich (ETH Zurich) and the city of Baden. With 96 participants and more than 30 speakers and panellists, the forum brought together leaders from government, academia, industry, and innovation ecosystems to explore how sustainability, Open Science, and innovation intersect in practice.
Why this mattered for MDPI
As a Swiss-based publisher with global reach, our investment in Z-Forum reflects a strategic intent: to anchor MDPI more deeply within Swiss research networks while contributing to national and international conversations on sustainability and innovation.
This was not only about visibility; it was also about relationship-building and long-term engagement with institutions shaping research policy and practice in Switzerland.
|
|
|
|
|
|
|
|
|
|
High-level participation and credibility
The forum was supported and sponsored by several key Swiss institutions, including:
- The Swiss National Science Foundation (SNSF) – Switzerland’s central research funding body
- ETH Zurich
- The University of Zurich
- The University of Basel
- Swiss Innovation Park Central
The sponsorship of SNSF lent the forum strong institutional credibility and signalled the relevance of the themes discussed, especially around sustainability, innovation frameworks, and responsible research practices.
|
|
|
Beyond the Room: Extending the Conversation
While attendance was intentionally focused to encourage dialogue, the forum’s reach extended well beyond the venue. Multiple LinkedIn posts before and during the event (e.g., Link 1, Link 2, Link 3, and more) built on the discussions and helped position MDPI as an active and credible contributor within Switzerland’s research and innovation landscape.
A Broader Strategic Signal
Z-Forum is part of a wider effort to:
- Build on MDPI’s Swiss institutional relationships
- Reinforce our leadership in Open Science and sustainability
- Engage proactively with funders, universities, and innovation bodies
- Ensure MDPI remains a visible and constructive partner in the ecosystems where research policy and practice are shaped
Thank you to our Conference team and everyone involved in supporting this event, both behind the scenes and on the ground. These moments of engagement may be small in scale, but they are foundational in impact.

Closing Thoughts

Reflections from the Academic Publishing in Europe Conference
During 13-14 January, I attended the Academic Publishing in Europe (APE) Conference in Berlin, a long-standing forum for discussing scholarly publishing and the deeper principles that support it.

MDPI was proud to be a Gold Sponsor of the 20th Anniversary of the APE conference, reflecting our continued commitment to supporting the scholarly community to engage in critical industry discussions.
This year’s program covered a range of topics, from AI and research integrity to policy, infrastructure, and trust, but one theme stood out clearly for me: academic freedom, and what it means to protect the conditions under which knowledge can be produced, evaluated, and shared responsibly.
Before turning to that, I would like to highlight the opening keynote by Carolin Sutton (CEO, STM), which helped set the tone for the conference.
An Independent Publishing Industry: The Case for Checks and Balances
In her opening remarks, Carolin focused on the importance of continually evolving systems of checks and balances, both operationally and at the marketplace level, to prevent any single actor from dominating knowledge production. Her framing emphasized shared responsibility across publishers, institutions, and research communities, rather than placing the burden on any one group.
As part of this, she revisited the work of sociologist Robert K. Merton, and his CUDOS norms of scientific ethos, first articulated in his 1942 work, The Normative Structure of Science.

Merton outlined four ideals that support healthy scientific systems:
- Communalism – knowledge as a public good
- Universalism – evaluation based on merit, not status or identity
- Disinterestedness – orientation toward truth over personal or financial gain
- Organized Skepticism – systematic, critical scrutiny of claims
While these are ideals, and not guarantees that are perfectly lived up to, they remain powerful reference points today for research systems and organizations as they aim to grow and scale.
It was interesting to see how closely these norms align with foundational principles of Open Access. For example, making research openly available supports communalism. Transparent peer review and editorial processes reinforce universalism and organized skepticism. Strong ethics frameworks and governance help counter conflicts of interest and support disinterestedness.
“Merton’s ideals remain powerful reference points today”
Safeguarding Research: Academic Freedom
Several of the conference sessions touched on the pressures faced by researchers, editors, and institutions: geopolitical tensions, online harassment, misinformation, reputational risk, shrinking resources, and politicized narratives around science.

“Integrity is not static. It must be actively maintained as systems grow.”
A particularly timely presentation came from Ilyas Saliba, who talked about academic freedom. His remarks resonated strongly and underlined the fact that safety in academia is not only physical or digital, but also intellectual.
Academic freedom means safeguarding the ability to ask difficult questions, challenge consensus, publish negative or unexpected results, and participate in scholarly debate without fear of undue personal, political, or commercial consequences. These discussions were a reminder that publishers play an important role in supporting the integrity, accessibility, and credibility of scholarly knowledge, particularly as researchers and institutions face mounting external pressures.
Looking Ahead
The discussions at APE reminded me that integrity is not static. It must be actively maintained as systems grow, expectations evolve, and pressures increase. This applies equally to research integrity, academic freedom, and the broader trust placed in scholarly communication.
I left APE encouraged by the openness of the dialogue and the willingness across publishers, institutions, and communities to engage with difficult questions rather than avoid them. Forums like this play a pivotal role in helping our industry pause, reflect, and recalibrate.
As MDPI continues to grow and as we enter our 30th anniversary, these conversations remind me of the core purpose of science: advancing knowledge for the benefit of society.
Chief Executive Officer
MDPI AG
2 February 2026
Recruiting Volunteer Reviewers for Current Oncology
Peer reviewing constitutes an essential part of the publication process, ensuring that Current Oncology (ISSN: 1718-7729) maintains its high standards in terms of the quality of its published papers. We are open to recruiting expert reviewers to help uphold the quality and efficiency of Current Oncology.
To qualify as a reviewer, applicants must have published eight papers related to the topics in the scope of Current Oncology in the last 5 years and hold a PhD or MD degree. You may check the “Peer Review” segment in the MDPI editorial process for details related to reviewers at the following link: https://www.mdpi.com/editorial_process. For example, reviewers should hold no conflicts of interest with any of the authors, reviewers should hold an official and recognized academic affiliation, etc.
We will extend the following benefits to reviewers:
- Reviewers will receive a discount voucher code based on review quality;
- Reviewers will be included in the journal’s annual acknowledgment of reviewers (example: https://www.mdpi.com/about/announcements/10400);
- Reviewers will be considered for the Current Oncology Outstanding Reviewer Award;
- Reviewers can build their profiles on Publons and have their reviewing activity automatically added for participating journals. Publons profiles can also be integrated into ORCID.
For more information about the role, please visit the following link: https://www.mdpi.com/reviewers.
If you are interested in this position, please submit your application at https://susy.mdpi.com/volunteer/journals/review. We hope that you will join our team of reviewers.
After your registration is approved, you will be able to see a list of manuscripts requiring reviewers.
If you have any other questions, please contact the Current Oncology Editorial Office. We look forward to hearing from you.
21 January 2026
Current Oncology | Top Cited Papers in 2025
1. “The Role of the DNA Methyltransferase Family and the Therapeutic Potential of DNMT Inhibitors in Tumor Treatment”
by Dae Joong Kim
Curr. Oncol. 2025, 32(2), 88; https://doi.org/10.3390/curroncol32020088
Available online: https://www.mdpi.com/1718-7729/32/2/88
2. “Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells”
by Tânia Moura, Paula Laranjeira, Olga Caramelo, Ana M. Gil and Artur Paiva
Curr. Oncol. 2025, 32(3), 143; https://doi.org/10.3390/curroncol32030143
Available online: https://www.mdpi.com/1718-7729/32/3/143
3. “Extramedullary Multiple Myeloma: Challenges and Opportunities”
by Matthew Ho, Luca Paruzzo, Janna Minehart, Neel Nabar, Julia Han Noll, Thomas Luo, Alfred Garfall and Saurabh Zanwar
Curr. Oncol. 2025, 32(3), 182; https://doi.org/10.3390/curroncol32030182
Available online: https://www.mdpi.com/1718-7729/32/3/182
4. “HPV and Cervical Cancer—Biology, Prevention, and Treatment Updates”
by Emilia Włoszek, Kamila Krupa, Eliza Skrok, Michał Piotr Budzik, Andrzej Deptała and Anna Badowska-Kozakiewicz
Curr. Oncol. 2025, 32(3), 122; https://doi.org/10.3390/curroncol32030122
Available online: https://www.mdpi.com/1718-7729/32/3/122
5. “Lung Cancer: Targeted Therapy in 2025”
by Nicole Bouchard and Nathalie Daaboul
Curr. Oncol. 2025, 32(3), 146; https://doi.org/10.3390/curroncol32030146
Available online: https://www.mdpi.com/1718-7729/32/3/146
6. “Cognitive Decline in Glioblastoma (GB) Patients with Different Treatment Modalities and Insights on Untreated Cases”
by Keyvan Ghadimi, Imane Abbas, Alireza Karandish, Celina Crisman, Emad N. Eskandar and Andrew J. Kobets
Curr. Oncol. 2025, 32(3), 152; https://doi.org/10.3390/curroncol32030152
Available online: https://www.mdpi.com/1718-7729/32/3/152
7. “Focal Therapy for Prostate Cancer: Recent Advances and Insights”
by Francesco Lasorsa, Arianna Biasatti, Angelo Orsini, Gabriele Bignante, Gabriana M. Farah, Savio Domenico Pandolfo, Luca Lambertini, Deepika Reddy, Rocco Damiano, Pasquale Ditonno et al.
Curr. Oncol. 2025, 32(1), 15; https://doi.org/10.3390/curroncol32010015
Available online: https://www.mdpi.com/1718-7729/32/1/15
8. “Nutritional Counseling During Chemotherapy Treatment: A Systematic Review of Feasibility, Safety, and Efficacy”
by Shalet James, Alexie Oppermann, Kaitlin M. Schotz, Mackenzie M. Minotti, Gautam G. Rao, Ian R. Kleckner, Brenton J. Baguley and Amber S. Kleckner
Curr. Oncol. 2025, 32(1), 3; https://doi.org/10.3390/curroncol32010003
Available online: https://www.mdpi.com/1718-7729/32/1/3
9. “Advancements in Locoregional Therapies for Unresectable Intrahepatic Cholangiocarcinoma”
by Conor D. J. O’Donnell, Umair Majeed, Michael S. Rutenberg, Kristopher P. Croome, Katherine E. Poruk, Beau Toskich and Zhaohui Jin
Curr. Oncol. 2025, 32(2), 82; https://doi.org/10.3390/curroncol32020082
Available online: https://www.mdpi.com/1718-7729/32/2/82
10. “Towards Personalized Radiotherapy in Pelvic Cancer: Patient-Related Risk Factors for Late Radiation Toxicity”
by Anna C. Nuijens, Arlene L. Oei, Nicolaas A. P. Franken, Coen R. N. Rasch and Lukas J. A. Stalpers
Curr. Oncol. 2025, 32(1), 47; https://doi.org/10.3390/curroncol32010047
Available online: https://www.mdpi.com/1718-7729/32/1/47
21 January 2026
Current Oncology | Top Cited Papers in 2024
1. “Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme—A Literature Review and Clinical Outcomes”
by Marcin Jezierzański, Natalia Nafalska, Małgorzata Stopyra, Tomasz Furgoł, Michał Miciak, Jacek Kabut and Iwona Gisterek-Grocholska
Curr. Oncol. 2024, 31(7), 3994-4002; https://doi.org/10.3390/curroncol31070296
Available online: https://www.mdpi.com/1718-7729/31/7/296
2. “Insulin Resistance: The Increased Risk of Cancers”
by Leszek Szablewski
Curr. Oncol. 2024, 31(2), 998-1027; https://doi.org/10.3390/curroncol31020075
Available online: https://www.mdpi.com/1718-7729/31/2/75
3. “Artificial Intelligence in Head and Neck Cancer: Innovations, Applications, and Future Directions”
by Tuan D. Pham, Muy-Teck Teh, Domniki Chatzopoulou, Simon Holmes and Paul Coulthard
Curr. Oncol. 2024, 31(9), 5255-5290; https://doi.org/10.3390/curroncol31090389
Available online: https://www.mdpi.com/1718-7729/31/9/389
4. “BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer”
by Sarah Lidagoster, Reuben Ben-David, Benjamin De Leon and John P. Sfakianos
Curr. Oncol. 2024, 31(2), 1063-1078; https://doi.org/10.3390/curroncol31020079
Available online: https://www.mdpi.com/1718-7729/31/2/79
5. “KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance”
by Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, Avrosina Kamel, Ariel Liberchuk and Andrew L. Wolfe
Curr. Oncol. 2024, 31(4), 2024-2046; https://doi.org/10.3390/curroncol31040150
Available online: https://www.mdpi.com/1718-7729/31/4/150
6. “Prehabilitation in Adults Undergoing Cancer Surgery: A Comprehensive Review on Rationale, Methodology, and Measures of Effectiveness”
by Carlos E. Guerra-Londono, Juan P. Cata, Katherine Nowak and Vijaya Gottumukkala
Curr. Oncol. 2024, 31(4), 2185-2200; https://doi.org/10.3390/curroncol31040162
Available online: https://www.mdpi.com/1718-7729/31/4/162
7. “Fertility Preservation in Cervical Cancer—Treatment Strategies and Indications”
by Lina Salman and Allan Covens
Curr. Oncol. 2024, 31(1), 296-306; https://doi.org/10.3390/curroncol31010019
Available online: https://www.mdpi.com/1718-7729/31/1/19
8. “Quality of ChatGPT-Generated Therapy Recommendations for Breast Cancer Treatment in Gynecology”
by Jan Lennart Stalp, Agnieszka Denecke, Matthias Jentschke, Peter Hillemanns and Rüdiger Klapdor
Curr. Oncol. 2024, 31(7), 3845-3854; https://doi.org/10.3390/curroncol31070284
Available online: https://www.mdpi.com/1718-7729/31/7/284
9. “Large Language Models in Oncology: Revolution or Cause for Concern?”
by Aydin Caglayan, Wojciech Slusarczyk, Rukhshana Dina Rabbani, Aruni Ghose, Vasileios Papadopoulos and Stergios Boussios
Curr. Oncol. 2024, 31(4), 1817-1830; https://doi.org/10.3390/curroncol31040137
Available online: https://www.mdpi.com/1718-7729/31/4/137
10. “Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer”
by Fabio Volpe, Carmela Nappi, Emilia Zampella, Erica Di Donna, Simone Maurea, Alberto Cuocolo and Michele Klain
Curr. Oncol. 2024, 31(7), 3870-3884; https://doi.org/10.3390/curroncol31070286
Available online: https://www.mdpi.com/1718-7729/31/7/286
13 January 2026
Current Oncology | Issue Cover Articles in 2025
The articles below have been selected as 2025 Issue Cover Articles by the Editorial Office of Current Oncology (ISSN: 1718-7729). These articles came from multiple fields within the scope of Clinical Oncology, and we hope they can provide insights and references for scholars in related fields.
![]() |
1. “Understanding the Immune System and Biospecimen-Based Response in Glioblastoma: A Practical Guide to Utilizing Signal Redundancy for Biomarker and Immune Signature Discovery” by Luke R. Jackson, Anna Erickson, Kevin Camphausen and Andra V. Krauze Curr. Oncol. 2025, 32(1), 16; https://doi.org/10.3390/curroncol32010016 Available online: https://www.mdpi.com/1718-7729/32/1/16 |
![]() |
2. “Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma” by Grace Wu, Oliver J. Standring, Daniel A. King, Sepideh Gholami, Craig E. Devoe, Cornelius A. Thiels, Travis E. Grotz, Matthew J. Weiss, Richard L. Whelan et al. Curr. Oncol. 2025, 32(2), 103; https://doi.org/10.3390/curroncol32020103 Available online: https://www.mdpi.com/1718-7729/32/2/103 |
![]() |
3. “HPV and Cervical Cancer—Biology, Prevention, and Treatment Updates” by Emilia Włoszek, Kamila Krupa, Eliza Skrok, Michał Piotr Budzik, Andrzej Deptała and Anna Badowska-Kozakiewicz Curr. Oncol. 2025, 32(3), 122; https://doi.org/10.3390/curroncol32030122 Available online: https://www.mdpi.com/1718-7729/32/3/122 |
![]() |
4. “Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment” by Saqib Raza Khan and Daniel Breadner Curr. Oncol. 2025, 32(4), 206; https://doi.org/10.3390/curroncol32040206 Available online: https://www.mdpi.com/1718-7729/32/4/206 |
![]() |
5. “Precision Medicine for Pediatric Glioma and NF1-Associated Tumors: The Role of Small Molecule Inhibitors” by Samuele Renzi, Julie Bennett, Nirav Thacker and Chantel Cacciotti Curr. Oncol. 2025, 32(5), 280; https://doi.org/10.3390/curroncol32050280 Available online: https://www.mdpi.com/1718-7729/32/5/280 |
![]() |
6. “Myelofibrosis: Treatment Options After Ruxolitinib Failure” by Ruth Stuckey, Adrián Segura Díaz and María Teresa Gómez-Casares Curr. Oncol. 2025, 32(6), 339; https://doi.org/10.3390/curroncol32060339 Available online: https://www.mdpi.com/1718-7729/32/6/339 |
![]() |
7. “Associations Between Symptom Complexity and Acute Care Utilization Among Adult Advanced Cancer Patients Followed by a Palliative Care Service” by Philip Pranajaya, Vincent Ho, Mengzhu Jiang, Vance Tran and Aynharan Sinnarajah Curr. Oncol. 2025, 32(7), 388; https://doi.org/10.3390/curroncol32070388 Available online: https://www.mdpi.com/1718-7729/32/7/388 |
![]() |
8. “Barriers and Enablers to Engaging with Long-Term Follow-Up Care Among Canadian Survivors of Pediatric Cancer: A COM-B Analysis” by Holly Wright, Sharon H. J. Hou, Brianna Henry, Rachelle Drummond, Kyle Mendonça, Caitlin Forbes, Iqra Rahamatullah, Jenny Duong, Craig Erker, Michael S. Taccone et al. Curr. Oncol. 2025, 32(8), 427; https://doi.org/10.3390/curroncol32080427 Available online: https://www.mdpi.com/1718-7729/32/8/427 |
![]() |
9. “Dual PET Imaging with [68Ga]Ga-DOTA-TOC and [18F]FDG to Localize Neuroendocrine Tumors of Unknown Origin” by Ali Zaidi, Pavithraa Ravi, Ingrid Bloise, Sara Harsini, Heather C. Stuart, Hagen F. Kennecke, Ian Alberts, François Bénard, Don Wilson, Patrick Martineau and Jonathan M. Loree Curr. Oncol. 2025, 32(9), 497; https://doi.org/10.3390/curroncol32090497 Available online: https://www.mdpi.com/1718-7729/32/9/497 |
![]() |
10. “A Goal Without a Plan Is Just a Wish—Creating a Personalized Aftercare Plan for Breast Cancer Patients Supported by the Breast Cancer Aftercare Decision Aid” by A. Dekker-Klaassen, C. H. C. Drossaert, R. Thé, A. M. Zeillemaker, M. van Hezewijk, I. M. De Keulenaar-Suiker, B. J. Knottnerus, A. Honkoop, M. L. van der Lee, J. C. Korevaar, S. Siesling and on behalf of the NABOR Project Group Curr. Oncol. 2025, 32(10), 552; https://doi.org/10.3390/curroncol32100552 Available online: https://www.mdpi.com/1718-7729/32/10/552 |
![]() |
11. “HPV Testing, Self-Collection, and Vaccination: A Comprehensive Approach to Cervical Cancer Prevention” by Shannon Salvador † on behalf of An Advisory Committee of Federal and Provincial Experts in Support of Reducing Cervical Cancer Incidence and Advancing Equitable Healthcare for Al Curr. Oncol. 2025, 32(11), 594; https://doi.org/10.3390/curroncol32110594 Available online: https://www.mdpi.com/1718-7729/32/11/594 |
![]() |
12. “Identification of Actionable Mutations in Metastatic Castration-Resistant Prostate Cancer Through Circulating Tumor DNA: Are We There Yet?” by Wensi Tao, Amanda Sabel and R. Daniel Bonfil Curr. Oncol. 2025, 32(12), 692; https://doi.org/10.3390/curroncol32120692 Available online: https://www.mdpi.com/1718-7729/32/12/692 |
13 January 2026
Current Oncology | Collection of Title Stories in 2025
We are pleased to present a selection of title stories published in Current Oncology (ISSN: 1718-7729) during 2025. These articles highlight groundbreaking research and advancements in clinical oncology, and we hope they can provide insights and references for scholars in related fields.
1. “Advancing Research Alongside Patient Partners: Next-Generation Best Practices for Effective Collaboration in Health Research”
by Ally C. Farrell, Jessica A. Lawson, Ovarian Cancer Canada’s Patient Partners in Research Team, Alison Ross and Alicia A. Tone
Curr. Oncol. 2024, 31(11), 6956-6978; https://doi.org/10.3390/curroncol31110513
Available online: https://www.mdpi.com/1718-7729/31/11/513
2. “The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers”
by Ryan Michael Antar, Christopher Fawaz, Diego Gonzalez, Vincent Eric Xu, Arthur Pierre Drouaud, Jason Krastein, Faozia Pio, Andeulazia Murdock, Kirolos Youssef, Stanislav Sobol et al.
Curr. Oncol. 2024, 31(11), 6909-6937; https://doi.org/10.3390/curroncol31110511
Available online: https://www.mdpi.com/1718-7729/31/11/511
3. “Malignant Pleural Effusion: Diagnosis and Treatment—Up-to-Date Perspective”
by Riccardo Orlandi, Andrea Cara, Enrico Mario Cassina, Sara Degiovanni, Lidia Libretti, Emanuele Pirondini, Federico Raveglia, Antonio Tuoro, Sara Vaquer, Stefania Rizzo et al.
Curr. Oncol. 2024, 31(11), 6867-6878; https://doi.org/10.3390/curroncol31110507
Available online: https://www.mdpi.com/1718-7729/31/11/507
4. “Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting”
by Filippo de Marinis, Andrea Ardizzoni, Ilaria Attili, Laura Bonanno, Emilio Bria, Diego Luigi Cortinovis, Stefano Margaritora, Francesca Mazzoni, Edoardo Mercadante, Alessandro Morabito et al.
Curr. Oncol. 2025, 32(2), 110; https://doi.org/10.3390/curroncol32020110
Available online: https://www.mdpi.com/1718-7729/32/2/110
5. “When “One Size Fits All” Fits None: A Commentary on the Impacts of the “Draft Canadian Breast Cancer Screening Guidelines” on Racialized Populations in Canada”
by Beverley Osei, Gayathri Naganathan, Juliet M. Daniel, Supriya Kulkarni, Aisha Lofters, Yinka Oladele, Leila Springer and Mojola Omole
Curr. Oncol. 2025, 32(3), 123; https://doi.org/10.3390/curroncol32030123
Available online: https://www.mdpi.com/1718-7729/32/3/123
6. “Feasibility and Acceptability of Social Prescribing for Cancer Survivors”
by Deirdre Connolly, Chloe O’Hara, Catherine O’Brien and Adrienne Dempsey
Curr. Oncol. 2025, 32(3), 129; https://doi.org/10.3390/curroncol32030129
Available online: https://www.mdpi.com/1718-7729/32/3/129
7. “Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma”
by Andrée-Anne Pelland, Mathilde Dumas, Émilie Lemieux-Blanchard, Richard LeBlanc, Julie Côté, Jean-Samuel Boudreault, Dominic Duquette, Rayan Kaedbey, Marc Lalancette, Frédéric Larose et al.
Curr. Oncol. 2025, 32(4), 238; https://doi.org/10.3390/curroncol32040238
Available online: https://www.mdpi.com/1718-7729/32/4/238
8. “Implementation of Organ Preservation for Locally Advanced Rectal Cancer in Canada: A National Survey of Clinical Practice”
by Megan Delisle, Victoria Ivankovic, Doris Goubran, Eliane Yvonne Paglicauan, Mariam Alsobaei, Nicole Alcasid, Mary Farnand and Kristopher Dennis
Curr. Oncol. 2025, 32(6), 341; https://doi.org/10.3390/curroncol32060341
Available online: https://www.mdpi.com/1718-7729/32/6/341
9. “Parents’ Experiences and Clinicians’ Perceptions of Managing Cancer Pain in Young Children at Home”
by Lindsay A. Jibb, Elham Hashemi, Surabhi Sivaratnam, Aimee K. Hildenbrand, Paul C. Nathan, Julie Chartrand, Nicole M. Alberts, Tatenda Masama, Hannah G. Pease, Lessley B. Torres et al.
Curr. Oncol. 2025, 32(10), 538; https://doi.org/10.3390/curroncol32100538
Available online: https://www.mdpi.com/1718-7729/32/10/538
10. “Cervical Cancer Screening Cascade: A Framework for Monitoring Uptake and Retention Along the Screening and Treatment Pathway”
by Sara Izadi-Najafabadi, Laurie W. Smith, Anna Gottschlich, Amy Booth, Stuart Peacock and Gina S. Ogilvie
Curr. Oncol. 2025, 32(7), 407; https://doi.org/10.3390/curroncol32070407
Available online: https://www.mdpi.com/1718-7729/32/7/407
11. “Methylation Status of the Telomerase Reverse Transcriptase Promoter in Parotid Tumours and Adjacent Parotid Gland Tissue: A Pilot Study on the Implications for Recurrence and Development of Malignancy”
by António Paiva-Correia, Joana Apolónio, Alfons Nadal, José Ricardo Brandão, Nádia Silva, Bianca Machado, Ivan Archilla, Pedro Castelo-Branco and Henrik Hellquist
Curr. Oncol. 2025, 32(6), 312; https://doi.org/10.3390/curroncol32060312
Available online: https://www.mdpi.com/1718-7729/32/6/312
12. “Dosimetric Comparison of VMAT Alone and VMAT with HDR Brachytherapy Boost Using Clinical and Biological Dose Models in Localized Prostate Cancer”
by Manuel Guhlich, Olga Knaus, Arne Strauss, Laura Anna Fischer, Jann Fischer, Stephanie Bendrich, Sandra Donath, Leif Hendrik Dröge, Martin Leu, Stefan Rieken et al.
Curr. Oncol. 2025, 32(6), 360; https://doi.org/10.3390/curroncol32060360
Available online: https://www.mdpi.com/1718-7729/32/6/360
13. “Renal Cell Carcinoma: Prognosis in the Era of Targeted Therapy”
by Kathrin Halfter, Michael Staehler, Dieter Hölzel, Alexander Crispin and Anne Schlesinger-Raab
Curr. Oncol. 2025, 32(9), 515; https://doi.org/10.3390/curroncol32090515
Available online: https://www.mdpi.com/1718-7729/32/9/515
9 January 2026
Cervical Cancer Awareness Month
In January, the WHO-recognized Cervical Cancer Awareness Month features global activities to raise awareness and support for Cervical Cancer research. We would like to take this opportunity to extend our appreciation to all of the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of Cervical Cancer that have been published in MDPI’s Journal Cluster of Oncology: Cancers, Current Oncology, Onco and Targets. We hope this announcement will provide useful information for all individuals interested in this field.

![]() |
![]() |
![]() |
![]() |

“Long-Term Outcomes of Co-Testing with 3-Type HPV mRNA (16/18/45) and Cytology in Women Under 40: A Real-World Cohort from Northern Norway (8–10 Years of Follow-Up)”
by Marie Bostrøm, Gunnar Skov Simonsen and Sveinung Wergeland Sørbye
Targets 2025, 3(4), 36; https://doi.org/10.3390/targets3040036
“The Role of Tissue Factor-Positive Microparticles in Gynecological Cancer-Associated Disseminated Intravascular Coagulation: Molecular Mechanisms and Clinical Implications”
by Muqaddas Qureshi, Muhammad Tanveer Alam and Ahsanullah Unar
Onco 2025, 5(3), 33; https://doi.org/10.3390/onco5030033
“The Neutrophil-to-Lymphocyte Ratio (NLR) as a Potential Predictor in Conization Outcomes for Cervical Cancer”
by Balázs Vida, Emese Keszthelyi, Zsófia Tóth, Lotti Lőczi, Barbara Sebők, Petra Merkely, Balázs Lintner, Ferenc Bánhidy, Attila Keszthelyi, Szabolcs Várbíró, Richárd Tóth and Márton Keszthelyi
Cancers 2025, 17(11), 1856; https://doi.org/10.3390/cancers17111856
“A Systematic Review of SBRT Boost for Cervical Cancer Patients Who Cannot Benefit from Brachytherapy”
by Iozsef Gazsi and Loredana G. Marcu
Curr. Oncol. 2025, 32(3), 170; https://doi.org/10.3390/curroncol32030170
“Neutrophil/Lymphocyte Ratio (NLR) as a Predictive Marker for p16 Positivity and Cervical Cancer Progression: Insights from the SCOPE Study”
by Zsófia Tóth, Lotti Lőczi, Barbara Sebők, Petra Merkely, Emese Keszthelyi, Balázs Lintner, Nándor Ács, Attila Keszthelyi, Szabolcs Várbíró, Richárd Tóth et al.
Cancers 2025, 17(6), 921; https://doi.org/10.3390/cancers17060921
“Molecular Insights into HR-HPV and HCMV Co-Presence in Cervical Cancer Development”
by Rancés Blanco and Juan P. Muñoz
Cancers 2025, 17(4), 582; https://doi.org/10.3390/cancers17040582
“Management for Cervical Cancer Patients: A Comparison of the Guidelines from the International Scientific Societies (ESGO-NCCN-ASCO-AIOM-FIGO-BGCS-SEOM-ESMO-JSGO)”
by Stefano Restaino, Giulia Pellecchia, Martina Arcieri, Giorgio Bogani, Cristina Taliento, Pantaleo Greco, Lorenza Driul, Vito Chiantera, Alfredo Ercoli, Francesco Fanfani et al.
Cancers 2024, 16(14), 2541; https://doi.org/10.3390/cancers16142541
“Impact of PET/CT Imaging with FDG in Locally Advanced Cervical Carcinoma—A Literature Review”
by Ottó Molnar, Oreste Mihai Straciuc, Simona Mihuțiu and Liviu Lazăr
Curr. Oncol. 2024, 31(5), 2508-2526; https://doi.org/10.3390/curroncol31050188
“The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)”
by Daniela Fischerova, Filip Frühauf, Andrea Burgetova, Ingfrid S. Haldorsen, Elena Gatti and David Cibula
Cancers 2024, 16(4), 775; https://doi.org/10.3390/cancers16040775
“Fertility Preservation in Cervical Cancer—Treatment Strategies and Indications”
by Lina Salman and Allan Covens
Curr. Oncol. 2024, 31(1), 296-306; https://doi.org/10.3390/curroncol31010019

| “Cervical Cancer Screening: Current Practices and Future Perspectives” Guest Editor: Dr. Kimon Chatzistamatiou Submission deadline: 20 March 2026 |
“Clinical Management of Cervical Cancer” Guest Editor: Dr. Vanessa Samouëlian Submission deadline: 31 March 2026 |
![]() |
![]() |
| “The Role of Minimally Invasive and Minimally Radical Surgery in Cervical and Endometrial Cancer” Guest Editors: Dr. Raj Naik, Dr. Marie Plante, Dr. Christophe Pomel, Prof. Dr. Roberto Tozzi and Dr. Gwénaël Ferron Submission deadline: 1 September 2026 |
“Medical Image-Based Cervical Cancer Prevention, Diagnosis, and Treatment” Guest Editors: Dr. Emma R. Allanson and Dr. Ming Yin Lin Submission deadline: 30 September 2026 |
![]() |
![]() |

![]() |
“Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer” Edited by Ranjit Manchanda https://doi.org/10.3390/books978-3-0365-2983-7 This is a Reprint of the Special Issue Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer that was published in Cancers. |
9 January 2026
MDPI’s Newly Launched Journals in December 2025
We have expanded our open access portfolio with eight new journals publishing their inaugural issues in December 2025, as well as three journal transfers. These additions span physical sciences, social sciences, arts and humanities, environmental and Earth sciences, medicine and pharmacology, and public health and healthcare. We extend our sincere thanks to the Editors-in-Chief, Associate Editors, and Editorial Board Members who are shaping these journals’ direction. All journals uphold strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.
Please feel free to browse and discover more about the new journals below.
|
New Journals |
Founding Editor-in-Chief(s) |
Journal Topics (Selected) |
|
|
Dr. Elisa Felicitas Arias, Université PSL, France |
atomic clocks; time and frequency metrology; GNSS systems; relativity and relativistic timekeeping; fundamental physics in space | |
|
|
Prof. Dr. José F.F. Mendes, University of Aveiro, Portugal |
complex systems; network science; nonlinear dynamics and chaotic behaviour; information theory and complexity; computational complexity | |
|
|
Prof. Dr. Roberto Morandotti, Institut National de la Recherche Scientifique—Énergie, Matériaux et Télécommunications (INRS), Canada |
light generation; light sources and applications; light control and measurement; human responses to light; lighting design | |
|
|
Prof. Dr. Savvas A. Chatzichristofis, Neapolis University Pafos, Cyprus |
generative AI and large language models in education; multimodal and embodied AI; personalization and adaptive systems; assessment, feedback, and academic integrity; learning analytics | |
|
|
Prof. Dr. Jon Andoni Duñabeitia, Universidad Nebrija, Spain |
cognitive psychology; cognitive neuroscience; psycholinguistics; applied linguistics; experimental psychology | |
|
|
Prof. Dr. Caiwu Fu, Wuhan University, China; Prof. Dr. Longxi Zhang, Peking University, China |
cultural practices; cultural theory; cultural policy; cultural heritage; transregional and transnational cultural flows| |
|
|
Dr. Ghassem R. Asrar, iCREST Environmental Education Foundation, USA |
biosphere interactions, processes, and sustainability; ecosystem science and dynamics; biodiversity conservation; global change and environmental adaptation; biogeochemical cycles | |
|
|
Dr. Giuseppe Mulè, University of Palermo, Italy |
cardiorenal syndromes; chronic heart failure and chronic kidney disease; cardiorenalmetabolic syndrome; hypertension and diabetes in relation to the abovementioned syndromes; diagnostic techniques | |
|
Transferred Journals |
Editor-in-Chief |
Journal Topics (Selected) |
|
|
Prof. Dr. Peter Matt, Lucerne Cantonal Hospital (LUKS), Switzerland |
cardiology; cardiovascular and aortic surgery; cardiovascular anatomy, physiology and pathophysiology; congenital heart disease and pediatric cardiology; cardiovascular regenerative and reparative medicine | |
|
|
Prof. Dr. Oana Săndulescu, Carol Davila University of Medicine and Pharmacy, Romania; National Institute for Infectious Diseases “Prof. Dr. Matei Bals”, Romania |
infectious diseases across clinical and public health domains; epidemiology of communicable diseases; clinical microbiology and applied virology; vaccinology and immunization; host–pathogen interactions and immunity | |
|
|
Dr. Roxana Elena Bohiltea, “Carol Davila” University of Medicine and Pharmacy, Romania |
public health; disease prevention; screening and early detection; lifestyle interventions and health education; digital and innovative prevention | |
We would like to thank everyone who has supported the development of open access publishing. If you would like to create more new journals, you are welcome to send an application here, or contact the New Journal Committee (newjournal-committee@mdpi.com).



































































